TransMedics Group (NASDAQ:TMDX - Get Free Report) will likely be announcing its Q1 2025 earnings results before the market opens on Thursday, May 8th. Analysts expect TransMedics Group to post earnings of $0.29 per share and revenue of $123.39 million for the quarter.
TransMedics Group Trading Down 0.7 %
NASDAQ:TMDX traded down $0.68 during midday trading on Friday, hitting $93.50. 1,295,458 shares of the company traded hands, compared to its average volume of 1,353,822. The firm's fifty day moving average is $74.46 and its 200-day moving average is $77.42. TransMedics Group has a 12-month low of $55.00 and a 12-month high of $177.37. The firm has a market capitalization of $3.16 billion, a P/E ratio of 99.47 and a beta of 2.14. The company has a current ratio of 8.20, a quick ratio of 7.33 and a debt-to-equity ratio of 2.42.
Analysts Set New Price Targets
A number of research firms have weighed in on TMDX. Canaccord Genuity Group reiterated a "buy" rating and issued a $104.00 target price on shares of TransMedics Group in a research note on Tuesday, March 11th. Needham & Company LLC reaffirmed a "hold" rating on shares of TransMedics Group in a research report on Wednesday. Three analysts have rated the stock with a hold rating, seven have issued a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $122.70.
Read Our Latest Analysis on TMDX
TransMedics Group Company Profile
(
Get Free Report)
TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.
Featured Stories
Before you consider TransMedics Group, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and TransMedics Group wasn't on the list.
While TransMedics Group currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Spring 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
